Acoustic Pulse Technology
Improving female fertility by stimulation of the reproductive system
The Problem
19% of couples fail to get pregnant after one year of trying (infertility)*
In 1/3 of the cases the origin of the fertility problem is in the woman and in 1/3 the origin is unknown.
* women aged 18 to 49 with no prior births, In the United States
Causes of female infertility include:
- Failure to Ovulate.
- Problems in the Menstrual Cycle.
- Structural Problems of the Reproductive System.
- Egg Maturity Problems
- Infections.
- Implantation Failure.
- Endometriosis.
- Polycystic Ovary Syndrome (PCOS)
Insufficient thickness in the Endometrium (< 7 mm) is considered as a major cause for embryo absorption difficulties .
Our Solution
Acoustic Pulse Technology (APT) is used to treat various inflammatory disorders. - such as wound healing, erectile dysfunction and heart ischemia.
Latica-Med Ltd. uses its innovative acoustic pulses technology (APT) to prepare women for the delicate IVF process, by treating most of the root-causes of infertility, including: Infections, implantation failures, endometrium thickness and Endometriosis.
The APT biologic mode of operation is scientifically proven for:
- Improve blood flow and angiogenesis
- Anti-inflammatory effect
- Increase in collagen i & III production
The treatment:
- Safe - no heating or radiation, no side effects reported
- Easily integrated into the regular IVF improcess
- Short and simple procedure (under 10 min)
The Market
Fertility market size 2020-2027
- Infertility affects more than 80 million couples worldwide
- 449 IVF clinics in US assisted yearly 326,468 reproductive cycles
- Globally, 2.5 million cycles are being performed every year
- Untapped (underserved) global market of $1B
IVF prevalence by country (IVF cycle per 10,000 People)
The Team
Eddie Papirov
Eddie Papirov
Eddie Papirov
Co-Founder, CEO/CTO An accomplished leader with 25 years of experience in medical device development and management. Founder of Hi-Impacts Ltd. and Armenta Ltd., with proven success in driving innovation and scaling companies to the sales stage. Former R&D Manager at Urogen Ltd. (Nasdaq) and key roles at GE Israel and Medispec Ltd. A seasoned electronics and computer science engineer and a proud Olympic athlete from Seoul '88
Dr. Sari Sagiv
Eddie Papirov
Eddie Papirov
Dr. Sagiv - Board Member possesses extensive expertise spanning more than 18 years in diverse domains of pharmaceutical and medical devices development, encompassing preclinical and clinical studies, regulatory affairs, and intellectual property. Currently serving as the VP of Research and Development at Gynica, a medical company dedicated to investigating and advancing cannabinoid solutions tailored to address gynecological symptoms and diseases.
Prof. Slomo Mashiah
Eddie Papirov
Yosh Dollberg
Prof. Slomo Mashiah - Advisory board chair One of the world’s leaders and pioneers in IVF. Former chief of dept. of Ob&Gynat Sheba Medical Center and president of the Association for the Fertility Study. Director of the IVF department (The largest in Israel ) at “Assuta” Medical Center, Tel Aviv. During the 35 years of Prof. Mashiah published hundreds of papers and has helped infertile couples to reproduce tens of thousands of children.
Yosh Dollberg
Yosh Dollberg
Yosh Dollberg
R&D and product management VP at hi-tech/device/ biotech companies, including DirexLtd. – a shockwaves systems vendor, Orbotech-AOI & OMS. UrogenPharma… BSc (Electrical Engineering – Technion). MSc studies (BIU), MBA studies (TAU). Part of Israel Security Prize project team.
Aleksandra Gomola
Yosh Dollberg
Kobi Kalderon
DACH Region Alliance.
Kobi Kalderon
Yosh Dollberg
Kobi Kalderon
MBA, International Strategic Alliance.